<DOC>
	<DOCNO>NCT02805556</DOCNO>
	<brief_summary>A phase I absolute bioavailability study BMS-626529 follow oral intravenous dose</brief_summary>
	<brief_title>Absolute Bioavailability BMS-626529 After Oral Intravenous Dosing</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Generally healthy BMI 18.032.0 kg/m2 Men sexually active woman childbearing potential must follow instruction contraception duration treatment plus 90 day Men must refrain sperm donation length study 90 day Sign inform consent Significant medical illness Tobacco use last 12 month Major surgery within 4 week study administration Donation blood within 4 week study administration Current recent ( within 3 month study administration ) gastrointestinal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>